FDA Advisers To Vote On Multi-Cancer Blood Test Recommendation

An independent panel of experts advising the U.S. Food and Drug Administration (FDA) is scheduled to vote on whether to recommend the Galleri blood test for regulatory approval. Developed by the company Grail, this test is designed to detect a wide range of cancers, specifically claiming the ability to identify signals from up to 50 different forms of the disease. The outcome of this vote is critical for the potential widespread adoption of the Galleri test in clinical settings, which could significantly alter cancer screening paradigms.

The Galleri test operates by analyzing cell-free DNA (cfDNA) in the blood, which is shed by tumors. By identifying specific patterns and methylation signatures within this DNA, the test aims to indicate the presence of cancer and, in many cases, suggest the tissue of origin. Grail has conducted extensive clinical trials, including the PATHFINDER study, to gather data supporting the test's efficacy and safety. The PATHFINDER study, which involved over 6,600 participants, demonstrated that the Galleri test could identify cancers that were not previously suspected, and subsequent diagnostic workups confirmed the presence of cancer in a significant proportion of positive results. The study also assessed the test's performance in identifying the tissue of origin, a crucial factor for guiding subsequent medical investigations.

Grail's proposed use for the Galleri test is as a supplemental screening tool, intended to be used alongside existing, recommended cancer screenings for individuals at higher risk due to age or other factors. The company emphasizes that the test is not meant to replace current screening methods for cancers like breast, colorectal, or lung cancer, but rather to complement them by detecting cancers that may not have routine screening protocols or are detected at later stages. The potential benefits include earlier detection, which is often associated with improved treatment outcomes and survival rates. However, the panel's recommendation will also consider potential risks, such as the possibility of false positive results leading to unnecessary anxiety and invasive diagnostic procedures, and false negative results providing a false sense of security.

The FDA's decision-making process involves a thorough review of the submitted data, including clinical trial results, analytical validation, and proposed labeling. The advisory committee's vote serves as a key input for the FDA, although the agency makes the final approval decision. The Galleri test has already received Breakthrough Device Designation from the FDA, indicating that it has the potential to offer a more effective diagnostic or therapeutic option for a life-threatening disease. This designation streamlines the development and review process. The panel's deliberation will likely focus on the test's clinical utility, its ability to improve patient outcomes, and the robustness of the data presented by Grail, particularly concerning its sensitivity and specificity across the broad spectrum of cancers it purports to detect.